<i>In Silico</i> Molecular Docking Study on <i>Soothagathai Udaika Kudineer: A Siddha</i> Medicine with the Target CYP-17-α Hydroxylase against Poly Cystic Ovarian Syndrome
Background: Poly Cystic Ovarian Syndrome (PCOS), in Siddha terms known as Sinaipaineer Katti, is the most common hormonal and reproductive disorder affecting women. It is marked by hyperandrogenism, hyperinsulinemia, and menstrual irregularities and also significantly contributes to mental health issues. The genes CYP11A, CYP17, and CYP19 encode enzymes involved in the steroidogenic pathway and are considered potential contributors to PCOS, leading to hyperandrogenism. Persistent hyperandrogenism causes menstrual irregularities such as amenorrhea (Soothaga Thadai), chronic anovulation, hirsutism, and infertility. Aim: To evaluate the interaction between phytoconstituents of the Siddha formulation Soothagathai Udaika Kudineer (SUK) and the target enzyme CYP-17α-hydroxylase through molecular docking analysis. Methods: A docking study was carried out to assess the interaction of nine phytocompounds found in SUK with CYP-17α-hydroxylase. Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters were added using Auto Dock tools. Results: The bioactive compounds present in SUK- Chlorogenic acid, gingerenone-A, kaempferitrin, diosgenin, and oleic acid- showed interaction with the active amino acids of CYP-17α-hydroxylase and exhibited strong binding affinity toward the enzyme. Conclusion: The inhibition of the target enzyme by these compounds suggests that they may act as therapeutic agents in the management of PCOS. SUK could serve as a safer alternative to existing treatments, which are often less effective or associated with adverse effects. 0 Major Findings: Key phytoconstituents in SUK showed strong binding with CYP-17α-hydroxylase, indicating their potential to inhibit androgen synthesis and help manage PCOS symptoms.